A SINGLE-CHAIN FV DERIVED FROM A FILAMENTOUS PHAGE LIBRARY HAS DISTINCT TUMOR TARGETING ADVANTAGES OVER ONE DERIVED FROM A HYBRIDOMA

Single-chain antibodies (scFvs) can be derived from a monoclonal antibody (MAb) or produced directly using filamentous phage technology, where antibodies with desired binding and purification characteristics can be readily selected from libraries. To test the hypothesis that the latter approach is more useful, we compared 2 anti-carcinoembryonic antigen (CEA) scFvs produced by these 2 different approaches. Our study showed that, both in the purification process and in the biodistribution pattern, MFE-23, produced by filamentous phage technology, gave favourable results compared to A5-SC, which is derived from the A5B7 MAb. This indicates the value of the filamentous phage approach for obtaining tumour-targeting scFvs. (C) 1995 Wiley-Liss, Inc.